| scholarly article | Q13442814 |
| P2093 | author name string | Wilson WH | |
| Pastan I | |||
| Kreitman RJ | |||
| Stetler-Stevenson M | |||
| Waldmann TA | |||
| Robbins D | |||
| Margulies I | |||
| P433 | issue | 10 | |
| P921 | main subject | refractory hairy cell leukemia | Q18557480 |
| hairy cell leukemia | Q201299 | ||
| P304 | page(s) | 3340-3348 | |
| P577 | publication date | 1999-11-01 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Responses in refractory hairy cell leukemia to a recombinant immunotoxin | |
| P478 | volume | 94 |
| Q36065616 | Ability of luteinizing hormone releasing hormone-Pseudomonas aeruginosa exotoxin 40 binding to LHRH receptor on human liver cancer cells |
| Q28085551 | Advances in anticancer immunotoxin therapy |
| Q34107825 | Antibody immunotherapy for leukemia |
| Q37611080 | Approach to the patient after relapse of hairy cell leukemia |
| Q42238468 | CD21(-/low) marginal zone B cells highly express Fc receptor-like 5 protein and are killed by anti-Fc receptor-like 5 immunotoxins in hepatitis C virus-associated mixed cryoglobulinemia vasculitis. |
| Q41149227 | Clinical targeting recombinant immunotoxins for cancer therapy |
| Q39046021 | Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells |
| Q37623386 | Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia |
| Q34444939 | Engineering toxin-resistant therapeutic stem cells to treat brain tumors |
| Q74267091 | Hairy cell leukemia |
| Q80214654 | Hairy cell leukemia |
| Q80731609 | Hairy cell leukemia |
| Q38124726 | Hairy cell leukemia-new genes, new targets |
| Q36328016 | Immunoconjugates in the management of hairy cell leukemia |
| Q79199423 | Immunotoxins for targeted cancer therapy |
| Q38201457 | Immunotoxins: a review of their use in cancer treatment |
| Q52716628 | Improving the in vivo efficacy of an anti-Tac (CD25) immunotoxin by Pseudomonas exotoxin A domain II engineering. |
| Q34657644 | Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples |
| Q35214050 | Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line |
| Q37843621 | Microbial-based therapy of cancer: current progress and future prospects |
| Q36366225 | Novel Therapy for Atherosclerosis Using Recombinant Immunotoxin Against Folate Receptor β-Expressing Macrophages |
| Q36058502 | Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia |
| Q36200380 | Pseudomonas exotoxin kills Drosophila S2 cells via apoptosis |
| Q37877743 | Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia |
| Q37165245 | Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies |
| Q37581788 | Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. |
| Q83629852 | Renal excretion of recombinant immunotoxins containing pseudomonas exotoxin |
| Q34657700 | Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. |
| Q37232738 | Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity |
| Q35653164 | Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy. |
| Q37452411 | The role of tregs in glioma-mediated immunosuppression: potential target for intervention. |
| Q35446333 | Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates |
| Q54979474 | Update on hairy cell leukemia. |
Search more.